(E/Z)-3-((3-(pyridin-3-yl)-1H-indazol-6-yl)methylene)indolin-2-one

ID: ALA4579738

PubChem CID: 135989019

Max Phase: Preclinical

Molecular Formula: C21H14N4O

Molecular Weight: 338.37

Molecule Type: Unknown

Names and Identifiers

Canonical SMILES:  O=C1Nc2ccccc2C1=Cc1ccc2c(-c3cccnc3)n[nH]c2c1

Standard InChI:  InChI=1S/C21H14N4O/c26-21-17(15-5-1-2-6-18(15)23-21)10-13-7-8-16-19(11-13)24-25-20(16)14-4-3-9-22-12-14/h1-12H,(H,23,26)(H,24,25)

Standard InChI Key:  NLPZXQSEMRVFPW-UHFFFAOYSA-N

Molfile:  

 
     RDKit          2D

 26 30  0  0  0  0  0  0  0  0999 V2000
   15.7162   -5.2404    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   16.4731   -4.9120    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   15.1723   -4.6216    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   15.5887   -3.9102    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   16.3993   -4.0920    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   16.9601   -3.4816    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   16.7113   -2.6890    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   15.8966   -2.5105    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   15.3395   -3.1224    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   15.5360   -6.0457    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   17.1827   -5.3333    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   17.9021   -4.9295    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   18.6089   -5.3512    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   18.6239   -3.7009    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   17.9078   -4.1064    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   19.3384   -4.1221    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   19.3276   -4.9455    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   20.1075   -5.2103    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   20.6003   -4.5504    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   20.1250   -3.8778    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   20.3897   -3.0971    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   21.1990   -2.9380    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   21.4640   -2.1581    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   20.9199   -1.5373    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   20.1076   -1.7018    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   19.8466   -2.4816    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  5  1  0
  4  3  1  0
  3  1  1  0
  4  5  2  0
  5  6  1  0
  6  7  2  0
  7  8  1  0
  8  9  2  0
  9  4  1  0
  1 10  2  0
  2 11  2  3
 11 12  1  0
 12 13  2  0
 13 17  1  0
 16 14  1  0
 14 15  2  0
 15 12  1  0
 16 17  2  0
 17 18  1  0
 18 19  1  0
 19 20  2  0
 20 16  1  0
 20 21  1  0
 21 22  2  0
 22 23  1  0
 23 24  2  0
 24 25  1  0
 25 26  2  0
 26 21  1  0
M  END

Alternative Forms

1. Parent:

   

   ALA4579738

   ---

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 338.37

Molecular Weight (Monoisotopic): 338.1168

AlogP: 4.12

#Rotatable Bonds: 2

Polar Surface Area: 70.67

Molecular Species: NEUTRAL

HBA: 3

HBD: 2

#RO5 Violations: ┄

HBA (Lipinski): 5

HBD (Lipinski): 2

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: 11.30

CX Basic pKa: 4.15

CX LogP: 3.40

CX LogD: 3.40

Aromatic Rings: 4

Heavy Atoms: 26

QED Weighted: 0.54

Np Likeness Score: -0.82

References

1. Li SW, Liu Y, Sampson PB, Patel NK, Forrest BT, Edwards L, Laufer R, Feher M, Ban F, Awrey DE, Hodgson R, Beletskaya I, Mao G, Mason JM, Wei X, Luo X, Kiarash R, Green E, Mak TW, Pan G, Pauls HW..  (2016)  Design and optimization of (3-aryl-1H-indazol-6-yl)spiro[cyclopropane-1,3'-indolin]-2'-ones as potent PLK4 inhibitors with oral antitumor efficacy.,  26  (19): [PMID:27592744] [10.1016/j.bmcl.2016.08.063]

Source

Source(1):

• Scientific Literature